PORTLAND, Ore.—A Microfluidic device created by a pair of professors from MIT and Harvard Medical School uses an internal detector studded with tiny carbon nanotubes to detect individual cancer cells in blood samples containing billions of healthy cells. About the size of a dime, the microfluidic sensor can also be functionalized to detect viruses as small as 40 nanometers
MIT professor Brian Wardle and Harvard Medical School professor Mehmet Toner say the microfluidic device should enable low-cost tests for diagnoses in-the-field by untrained personnel.
Previous prototypes used silicon posts as detectors—by attaching cancer antibodies to them—but even in a field of thousands of silicon posts, individual cancer cells could sometimes get through the microfluidic channels without encountering an antibody. The new design solves that problem by composing the posts out of hollow nanotube, thereby increasing the likelihood of detecting single cells by over eight times, according to Wardle and Toner.
The MIT/Harvard microfluidic detectors will flow blood samples through a field of up to 100 billion carbon nanotubes, enabling it to trap suspect cells of nearly any size—from micron-sized cancer cells to tiny viruses. Next, the researchers say they will redesign the microfluidic device to provide on-the-spot HIV diagnoses.
The first commercial versions of the MIT/Harvard microfluidic detector will take about two years to come to market, according to the researchers.
Posts just 30 microns in diameter are fashioned from bundles of hollow carbon nanotubes that can trap individual cancer cells as they flow through a microfluidic cancer detetor.
Image Source: Brian Wardle/MIT.
Yes, I agree. They probably are telling us how much more time they need to do the preliminary lab work before potential commercialization, which as you say, could take much longer (especially if they need regulatory approval from FDA, etc.)
Different antibodies can functionalize the sensor for detecting different things. The inventors only discuss detecting specific maladies, but potentially a whole variety could be screened simultaneously.
2 years till it is available commercially? I admire their optimism but not their hold onto reality. Medical product, new technology, 2 years .... seems very very unlikely.
Microfluidic detectors have been 2 years away from commercialization for at least 6-7 years. I have yet to see one in my doctor's office.
I think they have some great technology and it is certainly worthy of being available. I just highly doubt the final product development and all the necessary testing and approvals will be ready in that period of time.
Excellent two years to market, virus detection as well - does it have to be made special for each type of thing it is to detect or is it simply a receiver and some other device translates ?
Maybe next up - they will be able to do it with out blood - breath, or simply a light wave...
David Patterson, known for his pioneering research that led to RAID, clusters and more, is part of a team at UC Berkeley that recently made its RISC-V processor architecture an open source hardware offering. We talk with Patterson and one of his colleagues behind the effort about the opportunities they see, what new kinds of designs they hope to enable and what it means for today’s commercial processor giants such as Intel, ARM and Imagination Technologies.